Recently, Keever-Taylor et al. (102) showed that the manufacturing of autologous CD34+ cells in the “High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis” (HALT MS) and “Scleroderma: Cyclophosphamide or Transplantation” (SCOT) protocols was comparable across all transplantation centers and allowed successful granulocyte and platelet recoveries. This evidence concerns the gene CD34 and multiple sclerosis.